The banner and the Terms are describing different offers
A four-word promise runs across the top of every page on this site, including the Terms of Service page itself: no results, no charge. It is the kind of line a reader remembers and quotes back later.
The Terms tell a longer story. Subscription fees are non-refundable once fulfilment has begun. There is a prorated refund if a treatment becomes unavailable for supply or regulatory reasons. And there is a structured weight-loss guarantee, which requires satisfying all of a set of conditions — being a new customer, providing accurate enrolment information, and maintaining continuous enrolment for twelve consecutive months with no cancellation — before a refund is considered for someone who did not reach the target weight recorded at enrolment.
The price card carries an asterisk that points the same way, in smaller type: a twelve-month money-back guarantee applying to patients who complete twelve months of continuous enrolment and follow the prescribed programme, subject to eligibility criteria. So the footnote and the Terms agree with each other. It is the banner that is describing something else.
There is a third, unrelated no-charge promise on the same page, and it is worth separating out because it is straightforwardly true: if the reviewing physician decides the treatment is not appropriate for you, you are not charged. That is about eligibility, not results. Two very different promises share one phrase across this site.
The flat rate is real, and stated properly
The price card says the price is flat as the dose goes up, with no price increases. That is a specific, checkable claim, and it is the single most useful thing a compounded seller can say — Coby Health, also reviewed here, charges nearly double at maintenance dose than at the starting dose, and publishes the ladder to prove it.
The card also itemises what is in the figure: medication, clinician care and check-ins in one price, no insurance required, HSA and FSA eligible, cancel anytime with no long-term contract. The trust strip repeats no membership fees three times on the way down the page.
One wrinkle. The hero at the top of the same page introduces the figure with the word from. A price that is flat across all doses is not a from price, and a from price is not flat. Both phrasings are on the page, and only one of them can be right. Our row carries the flat-rate reading, because it is the one the pricing section makes as an explicit claim, and notes the other in the qualifier.
It names the medical group, and nobody in it
The footer of every page states that telehealth consultations are provided through a named partner medical group, with its website printed beside the name. That is a checkable disclosure and more than most of this roster offers on the clinical side — you can go and look at the company that employs the person who will be writing your prescription.
What you cannot do is find that person. No clinician is named anywhere. The site instead offers statistics: a hundred per cent board-certified prescribers, fifty-plus years of combined experience, ten thousand patients treated. Those are numbers about a group, and this comparison scores the question by whether a reader can look somebody up.
The pharmacy is not named either. The claim throughout is 503A and 503B certified pharmacies, which is a regulatory class, plus a footer note that medications may be fulfilled by partner pharmacies within the network unless you choose otherwise. That last clause is a small good thing: it implies you may direct a prescription elsewhere, the way Nu Image Medical says outright.
One more figure without a source: the page prints a reported success rate to one decimal place. There is no definition of success, no sample size, no period and no citation attached to it.
The programme has an ending, and the site says what it is
Almost nothing in this comparison addresses what happens after the weight comes off. Harbor does, in its own journey diagram: a structured, clinician-guided taper when you reach your goal, then registered-dietitian aftercare to hold the new baseline, described as a programme designed to end so the results last.
That is a real editorial position, and it is a commercially awkward one for a subscription business to publish. Whether the taper is delivered as described is not something a page read can establish. That it is described at all, on the pricing page, is unusual enough to note.
The corporate disclosure is complete: Harbor Health Inc., a Delaware corporation, with a principal place of business given as a suite number in Dover, Delaware, in the first section of the Terms and again in the arbitration notice clause. The Terms carry a last-updated date, which surprisingly few sellers here bother with.
It will not say where it operates
The Terms answer this one plainly and negatively: access may be limited by state licensure requirements or other regulatory considerations, and the company makes no representation that the services are available in every state.
There is no list anywhere — not on the homepage, not on either priced page, not in the Terms. The only related promise is per-patient, that every prescription is reviewed by a physician licensed in your state, which tells you about the review and nothing about whether you can enrol.
So our row records no states. A seller that says in writing it makes no representation about state availability has told you exactly what it knows, and inventing a coverage list on its behalf would be inventing the answer it declined to give.
Harbor's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $99/moPer month, flat across doses: "Simple pricing / One flat price, fully included / Semaglutide program / $99 /mo / Flat as your dose goes up, no price increases / Medication, clinician care, and check-ins in one price / No insurance required. HSA and FSA eligible / Cancel anytime, with no long-term contract". ⚠ The hero on the same page words it as "From $99/mo", which is a different claim from a flat rate. | September 2026source |
| Tirzepatide (compounded) | $149/moPer month. The tirzepatide page carries the same structure and the same flat-pricing claim, headlined "Start today for $149/mo · No results? No charge" and "From $149/mo"; the semaglutide page cross-references it as "Prefer tirzepatide? Tirzepatide $149/mo". | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 83 providers reviewed here are paid partners today; the other 79 are not. See how this works.
See Harbor's current price →Good fit if
- Readers who want a rate that does not climb as the dose does, stated as an explicit claim rather than implied.
- Buyers who want the partner medical group named and checkable, even if the individual clinician is not.
- People who want the end of treatment addressed — a taper and dietitian aftercare — rather than an open-ended subscription.
- Anyone who wants no membership fee, no long-term contract and no cancellation fee, all stated on the price card.
Look elsewhere if
- Anyone relying on the no-results-no-charge line. The refund it points at requires being a new customer and twelve consecutive months of unbroken enrolment, and fees are non-refundable once fulfilment begins.
- Readers who need their state confirmed. The Terms say the company makes no representation that the service is available in every state, and there is no list.
- Buyers who want the compounding pharmacy named. Ondra Health names six with their regulatory classes; Claya names two with street addresses and phone numbers.
- Patients who want a named prescriber. Emerge names its medical director with her board certification and residency; Shapely names eight clinicians.
- Anyone who wants a brand-name GLP-1. No brand product or brand price is published here.
How this review was verified
- Re-read the homepage, both priced pages, the my-health-my-data page and the full Terms of Service on 6 September 2026, rather than carrying any figure across from the research file that nominated this seller — which is how we found that its headline contradiction about this site no longer exists.
- Printed the status, byte size and effective URL of every fetch and compared the effective path to the requested one, so a redirect could not be mistaken for a page.
- Ran a nonsense path against this host in the same run as every read. It returned 404 with roughly 29,600 bytes of shell attached each time, which is why nothing here was judged by page size.
- Extracted every figure from a Python html.parser pass over text nodes only, with residual markup asserted absent.
- Read the refund clause in the Terms in full before writing about the banner, and quoted both texts rather than characterising either.
- Recorded the flat-rate reading of the price and put the seller's own from wording into the qualifier beside it, so the inconsistency travels with the figure.
- Recorded the states field as empty on the strength of the Terms' own sentence declining to represent availability, rather than inferring coverage from a licensing promise about prescription review.
- Screened the legal entity against FDA's live warning-letter record with a positive control and a nonsense-string negative control in the same run. No letter to this entity appeared; untitled letters are published separately and were not searched.